Premium
Response to altitude and intermittent normobaric hypoxia (INH)
Author(s) -
Cardoso S,
Samillan V,
Pereira P,
Werneck M,
Quispe M,
Amaral M,
Romeo J,
Rozeira C,
Horowitz M
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.938.7
Subject(s) - medicine , hypoxia (environmental) , copd , insulin resistance , fructosamine , inhalation , endocrinology , insulin , physiology , anesthesia , oxygen , chemistry , organic chemistry
Hypoxic (HIF‐1) interventions enhance antioxidant capabilities; repair & regeneration defenses while preparing organisms for subsequent similar or even harsher stressors. More recent studies (Samillan, et. al., Hypoxia Consequences, NYAS 2009) support the clinical use of hypoxic interventions in the management of human T2D, hypertension, CV, & pulmonary disease. Reponses to altitude and INH in young control subjects (Peru) and patients with either T2D or COPD was studied. Inhalation of gas mix (pp O15 + N85) or interrupting nasal oxygen flow in pts c/COPD/Stage IV was used. OGTTs and determinations of glucose, insulin, fructosamine, HBA1c, reticulocytes (7AM‐11AM) were made. Controls (Peru, N=20, reticulocytosis) had lower levels of glucose and insulin at 2hrs post glucose administration (P,<0.0001). T2D (Brazil, N=5) had lower blood glucose (P=0.09). COPD and improved SpO2 levels were found after 5 INH/5 wks (P<0.035). These results suggest that patients will respond to INH with improved quality of life, increased tolerance to exercise, partial corrections of glucose intolerance, insulin resistance and, in general, lower dose/frequency of prescribed Rx. Support: San Pedro U., Peru. Private donations, clinical assistance by Servico Unico De Saude and Lab Araruama, Brazil.